Evidence map›Paper›PMID 40855033›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Compact accelerator-based production of carrier-free

Austin A Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Austin A MorrisState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China.
Tianhao WeiState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China.
Zhi WangState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China.
Ying XiaState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China.
Meiyun HanState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China.
Yuanrong LuState Key Laboratory of Nuclear Physics and Technology, Peking University, 5 Yiheyuan Rd., Beijing, 100871, China. yrlu@pku.edu.cn.ORCID http://orcid.org/0000-0002-2639-8112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent EMA and FDA approvals of Lu-DOTATATE and Lu-PSMA-617 have led to increased demand for radiotherapeutic

resultsA circular target with a radius of 1 cm and 0.36 mm thickness is selected to optimize the yield of

conclusionsThe study confirms the feasibility of accelerator-based

Indexed as

Linear acceleratorLutetium(Neuroendocrine cancerRadiopharmaceuticalYtterbium(

Identifiers

PMID40855033
PMCPMC12379675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.